ASX Announcement

13 August 2024

Neurotech to present at Investor Verse Biotech Workshop

Neurotech International Limited (ASX: NTI) ("Neurotech" or "the Company"), a clinical-stage biopharmaceutical development company focused predominately on paediatric neurological disorders, today is pleased to announce that it will present at the Investor Verse Biotech Workshop to be held today.

Shareholders, investors and interested parties can register and join the live stream at the following link:

Join Zoom Meeting
https://us06web.zoom.us/j/86414258050?pwd=ilYKG1PpyATPAbbMeJ3MnYDNkMo3Aj.1

Meeting ID: 864 1425 8050
Passcode: Skillion

Executive Director Dr Thomas Duthy's presentation will be held from approximately **6.15pm AEST**.

A copy of the presentation is attached.

Authority
This announcement has been authorised for release by the Board of Neurotech International Limited.

Further Information
Dr Thomas Duthy
Executive Director
td@neurotechinternational.com
+61 (0)402 493 727

About Neurotech

Neurotech International Limited (ASX:NTI) is a clinical-stage biopharmaceutical development company focused predominately on paediatric neurological disorders. Neurotech has completed a Phase I/II clinical trial in Autism Spectrum Disorder (ASD), which demonstrated excellent safety and efficacy results at 28 days, 20 weeks and 52 weeks of treatment with NTI164. The Company has commenced a Phase II/III randomised, double-blind, placebo-controlled clinical trial in ASD, and completed a Phase I/II trial in Rett Syndrome and in Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and Paediatric Acute-Onset Neuropsychiatric Syndrome (PANS), collectively PANDAS/PANS. In addition, Neurotech has received human ethics committee clearance for a Phase I/II clinical trial in spastic cerebral palsy.

For more information about Neurotech please visit http://www.neurotechinternational.com.

Improving Lives

Neurotech International

Investor Verse Biotech Workshop Presentation

Dr Tom Duthy
Executive Director

13 August 2024

Disclaimer

IMPORTANT INFORMATION

Purpose of presentation: This presentation (including this document, any related video or oral presentation, any question and answer session and any written or oral material discussed or distributed in relation to this presentation) has been prepared by Neurotech International Limited (ACN 610 205 402) (Neurotech or Company). It has been prepared for the sole purpose of providing general information on Neurotech and its business.

Not an offer or solicitation: This presentation is not investment advice nor an offer to subscribe for securities or otherwise invest in Neurotech, and it should not be relied upon to make any investment decision. Further, it does not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of securities pursuant to this presentation in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful under applicable law, including the Securities Act of 1933 (USA), as amended (US Securities Act). Securities have not been registered under the US Securities Act or any US state securities laws and may not be offered or sold in the United States absent registration or an applicable exemption from registration under the US Securities Act and applicable state securities laws.

Not a prospectus: This presentation is not a prospectus, product disclosure statement or other investment disclosure document, and the level of disclosure in this presentation is less than such disclosure documents. It has not been lodged with any regulatory or supervisory body. This presentation does not purport to contain all of the information that a prospective investor may require to make an evaluation of Neurotech or its business activities and nothing in this presentation is, or is intended to be, a recommendation to invest in Neurotech. Neurotech does not purport to give financial or investment advice. Account has not been taken of the objectives, financial situation or needs of any recipient of this presentation.

Forward-looking statements: This presentation contains forward-looking statements which may be predictive in nature and incorporate an element of uncertainty or risk, such as ‘intends’, ‘may’, ‘could’, ‘believes’, ‘estimates’, ‘targets’ or ‘expects’. These statements are based on an evaluation of current economic and operating conditions, as well as assumptions regarding future events. These events are, as at the date of this presentation, expected to take place, but there cannot be any guarantee that such will occur as anticipated, or at all, given that many of the events are outside Neurotech’s control. The stated events may differ materially from results ultimately achieved. Accordingly, neither Neurotech nor any of its directors, employees, contractors or advisors make any warranty or assurance that the results, performance or achievements expressed or implied by the forward-looking statements contained in this presentation will actually occur. Further, other than as required by law, Neurotech may not update or revise any forward-looking statement if events subsequently occur or information subsequently becomes available that affects the original forward-looking statement.

Disclaimer: Neither Neurotech nor its officers, employees, contractors or advisers make any warranty (express or implied) as to the accuracy, reliability, relevance or completeness of the material contained in this presentation. Nothing contained in this presentation is, or may be relied upon as a promise, representation or warranty, whether as to the past or the future. Neurotech excludes all warranties that can be excluded by law. Except for statutory liability which cannot be excluded, Neurotech, its officers, employees, contractors and advisers expressly disclaim any responsibility for the accuracy or completeness of the material contained in this presentation and exclude all liability whatsoever (including in negligence) for any loss or damage which may be suffered by any person as a consequence of any information in this presentation or any error or omission therefrom.

Professional advice: Recipients of this presentation should consider seeking appropriate professional financial, taxation and legal advice in reviewing the presentation and all other information with respect to Neurotech and evaluating its business, financial performance and operations.

Corporate / Capital Summary

$0.065
Share price
(as at 9 Aug 2024)

$66.1M
Market capitalisation

$11.6M
Cash 30 June ’24

~2,540
No. of shareholders

1017.3M
Share on issue

176.5M
Options^

$6.8M
FY24 cash R&D.
(up from $6.4M in FY23)

44.2%
Top 20 Holders

- ^Inc Listed, Unlisted Investor Options, Executive, Director options at various strike prices between $0.06 to $0.16 as at 9 August 2024

Neurotech Four Core Strategies

Neurotech International



Focus on Paediatric Patients



Focus On Rare Neurological Disorders with Neuroinflammation

Focus on Partnering with Key Opinion Leaders / Clinicians



Focus On Drug Product Development

Therapeutic Agent: NTI164

Neurotech International

High potency, Broad Spectrum Cannabinoid Formulation in Oil Designed for Children (1/2x per day)

How does it work?

- **Entourage Effect**
  (led by CBDA, cannabinoids work better together)
- **Neuroprotective**
  (protects neurons from damage, promotes regeneration)
- **Anti- Neuroinflammatory**
  (sig. reduces inflammation that causes neuronal damage)

Is it Safe?

- Kidney/Liver Function – Blood Chemistry – Vital Signs
  All normal
- Mild Nausea/vomiting ~5-15%
  (max. first few weeks upon initiation of therapy)
- No Weight Loss
- No Diarrhoea

Single Patient Urticaria/Hives
(1% of total pts)

NTI164 – Ideal Target Product Profile

- **Prescription Only Medicine**
- **FDA, EMA, TGA Approved**
- **Multiple Paediatric Neurological Disorders**
- **Premium Pricing Reflecting Clinical Investment**
- **Reimbursed**
- **Orphan Designations + Other Regulatory Levers**

1. Based on 73m children with 1/15,700 living with disease
2. https://www.lgsfoundation.org/
3. Tuberous Sclerosis Complex (TSC)
4. Jazz Pharmaceuticals

Clinical Pipeline – 2024

Neurotech International

Pre-Clinical

- Other Licensed Strains
- Synthetic Cannabinoid(s) combinations

Phase I/II

- NTI164 Cerebral Palsy
- NTI164 PANDAS / PANS[1]
- NTI164 ASD[2] (NTIASD1) (90 week+ open label extension)
- NTI164 Rett Syndrome

Phase II/III

- NTI164 ASD (NTIASD2)

World-first clinical trials, and first time substantial clinical benefit shown with a broad-spectrum cannabinoid drug therapy

Data reported (all with statistically significant primary endpoint results + large number of secondary endpoints)

1. Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and Paediatric Acute-Onset Neuropsychiatric Syndrome (PANS)
2. Autism Spectrum Disorder

Autism | Rett | PANDAS/PANS

Neurotech International

*"The goals of treatment for **Autism** are to improve core deficits in social communication and social interactions and minimize the impact of restricted behaviours, with an overarching goal to help children develop greater functional skills and independence."* [1]

*"Caregivers of children with **Rett** experience the illness as being like an "obstacle course", where they must continuously overcome hurdles. These include hindrances for finding responses to their symptoms and achieving a diagnosis, for managing the treatment and daily care, and for finding the essential financial resources to meet all the expenses generated by the illness."* [2]

*"We encourage clinicians, teachers, providers, extended family, and friends to understand the human aspects of **PANDAS/PANS** as symptoms are often so distressing, causing high levels of caregiver burden."* [3]

1. Weitlauf AS, McPheeters ML, Peters B, et al. Therapies for Children With Autism Spectrum Disorder: Behavioural Interventions Update. Rockville (MD): Agency for Healthcare Research and Quality (US); 2014 Aug. (Comparative Effectiveness Review, No. 137.) Introduction.
2. Palacios-Ceña D, Famoso-Pérez P, Salom-Moreno J, Carrasco-Garrido P, Pérez-Corrales J, Paras-Bravo P, Güeita-Rodriguez J. "Living an Obstacle Course": A Qualitative Study Examining the Experiences of Caregivers of Children with Rett Syndrome. International Journal of Environmental Research and Public Health. 2019; 16(1):41
3. https://aspire.care/what-is-pans/caregiver-experience/

Intellectual Property – 2024

Strong Patent Position

Neurotech has three patent families to underpin future worldwide commercialisation in neurological applications of NTI164. Two families have now entered the national phase and one family has entered the international (PCT) phase.

Composition

Uniqueness of the NTI-164 strain – composition profile with low THC (<0.3%) and a unique combination of 'rarer' cannabinoids: CBDA, CBC, CBDP, CBDB & CBN

Lodged Oct 2021

Combination

The application, formulation and use of NTI164

Lodged Oct 2021

Methods

The application, formulation and use of NTI164 in paediatric patients

Lodged Oct 2022

Other IP & Barriers to Entry

Vertically Integrated: Seed to Patient Controlled

(Trade Secret: continuity of production to SOP, extraction(s))



Orphan Drug Designation(s)

10 Years	Market Exclusivity from Approval – Europe
7 Years	Market Exclusivity from Approval – United States

PANDAS/PANS

Rett Syndrome

Pending

Clinical Trials, Treatment Durations

All patients can continue on NTI164 ‘extension’ – additional long-term safety and efficacy collected





94

Children treated with NTI164 in a clinical trial and extension studies

2+

Years of daily oral treatment with NTI164 and counting



Not to Scale

NT1164 Efficacy is Strong, Durable and Consistent

Neurotech International

Autism (Phase II/III)

56% Improvement in Severity of illness at 12 weeks



46% Patients Much Improved / Improved at 8 weeks

Significant Improvements in Adaptive Behaviours

Rett

100% of patients improved by week 20



57% of patients "very much / much improved"

60% Improvement in patient/caregiver quality of life

PANDAS/PANS

38% Improvement in Disease Severity at 52 weeks



45% Improvement in anxiety / depression at 52 weeks

2024 Corporate Strategy

Global Partnering

- Secure one or more strategic partnerships for NTI164 in the United States, Europe and certain Asian territories to support clinical, regulatory development, manufacturing and future market launches
- In 2023, at least 49 deals were announced involving rare neurological diseases, with disclosed values totalling US$13.2 billion

AU Registration(s)

- Seek provisional registration pathway for NTI164 initially for either PANDAS/PANS or Rett Syndrome (i.e. the orphan disease franchise)
- Provisional registration(s) can save up to two years of development and a provisionally registered prescription medicine may be able to receive reimbursement. Follow with ASD (large market in AU)

2024 Corporate Strategy

Global Partnering

Neurotech International

Partnering Example – Plant Derived High Dose Cannabinoid (CBD) Drug

Epidiolex®
(High Dose CBD Oil)

- Three rare paediatric epileptic disorders (DS, LGS, TSC) total patients **29,000**
- Developer (GW Pharma) acquired by Jazz Pharma (2021) **US$7.2B**
- 2022 Sales **US$731M**
- 2024 sales expectations **US$1Bn**
- Sales Compound Annual Growth Rate (CAGR) 2018-2022 **253%**

Partnering Example –Rare Paediatric Neurological Disorders

neuren pharmaceuticals

(ASX:NEU), Market Cap: $2Bn

- US$1 billion global license deal for DAYBUE™ (trofinetide) with 10-20% royalties on sales
- One indication - Rett Syndrome US$2 billion annual market opportunity

ACADIA® Pharmaceuticals

(NASDAQ:ACAD), Market Cap: US$6.8Bn

Source: Jazz Pharma, Neuren Pharma, Acadia Pharma; DS - Dravet Syndrome, LGS - Lennox Gastaut Syndrome , TSC – Tuberous Sclerosis Complex

2024 Corporate Strategy

AU Registration(s)

Neurotech International

Australian Market

Rett Syndrome: 380 pts | threshold to pay N/A | Market N/A

PANDAS/PANS: 1000 pts | threshold to pay $100k | Market $100m

ASD: 169k pts | threshold to pay $35.3k | Market $5.9Bn[1]

Global (US,EU) Market

Rett Syndrome: 9,500 pts | threshold to pay N/A | Market US$2Bn

PANDAS/PANS: 14,000 pts | threshold to pay US$100k | Market US$1.2Bn

ASD: 4.2m pts | threshold to pay N/A | Market US$3⁺Bn[1]

1. The AU market based on threshold to pay calc. on NDIS recipients for NTI264, whereas US/EU based on Market Reports (Grandview Research, Virtue Market Research) on current drugs used
N/A – Not available. **Source:** Neurotech market estimates, Neurotech Presentations, ASX Release 12 August 2024 based on various data sources, Neuren Pharma presentation dated 28 August 2023.

Key Milestones – NTI164

1H CY2024

- HREC/TGA Approval Cerebral Palsy Phase I/II Clinical Trial
- 24-week PANDAS/PANS Phase I/II Clinical Trial Data
- Rett Syndrome Phase I/II 52-week Extension HREC Approval
- Results of ASD Phase II/III Clinical Trial
- Top-line Rett Syndrome Phase I/II Clinical Trial data
- Results of Rett Syndrome Phase I/II Clinical Trial – full data
- Meeting outcome – TGA[1] Regulatory Advice
- Metabologenomic data from Phase I/II PANDAS/PANS Clinical Trial
  - Pending final analysis by Prof. Dale team (Q3)

2H CY2024

- Appointment of A/Prof Carolyn Ellaway as CMO
- Filing of Orphan Drug Designation USA – PANDAS/PANS
- Additional Phase II/III 12 Week Cross-Over Results - ASD
- Orphan Drug Designation USA – Rett Syndrome
- Orphan Drug Designation USA – PANDAS/PANS
- Orphan Drug Designation Europe – Rett Syndrome
- Orphan Drug Designation Europe – PANDAS/PANS
- Presentation of Phase I/II Rett Syndrome data at international Rett meeting
- FDA IND / EMA[2] toxicology
- Commence Phase I/II Cerebral Palsy Clinical Trial
- Publications for ASD Phase I/II + pre-clinical NTI164 results (was 1H)

1. Therapeutic Goods Administration (TGA)
2. Food and Drug Administration (FDA), European Medicines Agency (EMA)

Neurotech International

Contact Details

Dr Tom Duthy
Executive Director
td@neurotechinternational.com
+61 402 493 727

*This presentation has been authorised by the Board of Neurotech International Limited

www.neurotechinternational.com